Research Papers:

The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria

Satoshi Tamada _, Taro Iguchi, Sayaka Yasuda, Minoru Kato, Takeshi Yamasaki and Tatsuya Nakatani

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:27752-27759. https://doi.org/10.18632/oncotarget.25554

Metrics: PDF 1311 views  |   HTML 1493 views  |   ?  


Satoshi Tamada1, Taro Iguchi1, Sayaka Yasuda1, Minoru Kato1, Takeshi Yamasaki1 and Tatsuya Nakatani1

1Department of Urology, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka 545-8585, Japan

Correspondence to:

Satoshi Tamada, email: [email protected]

Keywords: molecular targeted therapy; renal cell carcinoma; Memorial Sloan Kettering Cancer Center criteria; metastasis; intermediate risk

Received: April 23, 2018     Accepted: May 18, 2018     Published: June 12, 2018


Objectives: To investigate the necessity of stratifying patients in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center (MSKCC) criteria in a real-world population of patients with metastatic renal cell carcinoma.

Patients and Methods: We retrospectively analyzed 234 consecutively treated patients who had received molecular targeted drugs. We examined the difference between progression-free survival and overall survival among patients in the intermediate-risk group of MSKCC criteria. We divided the intermediate group into two subgroups as follows: patients positive for only one risk factor (Int-1) and those positive for two risk factors (Int-2) including performance status, serum hemoglobin level, time from diagnosis to treatment, and corrected calcium and lactate dehydrogenase levels. Next, we evaluated the association between the number of metastatic organs, the presence of pancreatic metastasis, Int-1 or Int-2 grouping, and overall survival.

Results: The median overall survival was 41.2 months. The median overall survival of the favorable-, intermediate-, and poor-risk groups of the MSKCC criteria were 91.0, 33.6, and 15.2 months, respectively. Patient characteristics were similar between the Int-1 and Int-2 groups. Increased positivity for risk factors of MSKCC classification between the two groups was for performance status and serum hemoglobin level. Progression-free survival and overall survival of the Int-1 group were significantly higher than those of the Int-2 group. In Cox proportional stepwise multivariate analysis, the Int-1 and Int-2 classification was an independent risk factor for overall survival.

Conclusion: Patients in the intermediate-risk group had different prognoses depending on the number of positive risk factors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25554